Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2003

01-08-2003 | Originales

CHOP con intensificación de dosis en linfomas no Hodgkin agresivos

Authors: Beatriz Alonso Álvarez, Marta Llanos Muñoz, María Remedios Alemán Valls, Juana Oramas Rodríguez, Luz Milva Rodríguez Rodríguez, Josefina Cruz Jurado, Javier Dorta Delgado, José Aguiar Morales, Adolfo Murias Rosales, Y Norberto Batista López

Published in: Clinical and Translational Oncology | Issue 6/2003

Login to get access
Metadata
Title
CHOP con intensificación de dosis en linfomas no Hodgkin agresivos
Authors
Beatriz Alonso Álvarez
Marta Llanos Muñoz
María Remedios Alemán Valls
Juana Oramas Rodríguez
Luz Milva Rodríguez Rodríguez
Josefina Cruz Jurado
Javier Dorta Delgado
José Aguiar Morales
Adolfo Murias Rosales
Y Norberto Batista López
Publication date
01-08-2003
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 6/2003
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/BF02709990

Other articles of this Issue 6/2003

Clinical and Translational Oncology 6/2003 Go to the issue

Artículo Especial

Lenguaje oral y escrito: ¿hemos mejorado los oncólogos?

Originales

The Borrmann classification. Interobserver and intraobserver agreement of endoscopists in an oncological hospital

Announcement

Información

Originales

Experiencia en la utilización del fentanilo transdérmico en un servicio de Oncología radioterápica

Editorial

The role of surgery in hereditary breast cancer prevention

Notas Clínicas

Multiple neuroblastoma or multiple diseases?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits